- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01495884
The Myocet/Lapatinib Study. ICORG 10-03, V5
A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes
This study is a Phase I/II open label, multi-centre trial. Patients with HER2+ve metastatic breast cancer, following disease progression during, or after, treatment with trastuzumab and taxanes, will be treated with Lapatinib (Tyverb™ 500-1250 mg orally daily - depending on the maximum tolerated dose (MTD) determined in the Phase I part of the study) plus Myocet™, 50-60 mg/m2 i.v q3 weeks).
Within the Phase I part, doses are assigned at registration according to the dose escalation scheme.
The dose for the Phase II part of the trial will be based on the MTD established in the Phase I part of the study.
Clinical and laboratory parameters will be assessed to evaluate disease response and toxicity of study therapy. Safety assessments will be performed every 3 weeks for the first 24 weeks. Efficacy assessments (radiological examination) will be performed on all patients every 8 weeks (± 7 days) for the first 24 weeks. Cardiotoxicity assessments will be performed at weeks 6 and 12. From week 24, safety, efficacy and cardiotoxicity assessments will be performed every 12 weeks and at the end of treatment (disease progression, unacceptable toxicity or patient withdraws consent).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
- To determine the optimal dose for lapatinib plus Myocet™, in combination, in patients with HER2-positive metastatic breast cancer following disease progression during, or after, treatment with trastuzumab and taxanes (Phase I).
- To evaluate the 6 month progression-free survival of patients with HER2-positive metastatic breast cancer, following disease progression during, or after, treatment with trastuzumab and taxanes, who are treated with lapatinib plus Myocet™ (Phase II plus patients treated at MTD in Phase I).
Secondary Objectives:
- To evaluate the overall survival time, duration of progression -free survival, time to treatment failure, confirmed tumour response rate and duration of response in patients treated with this regimen (Phase II plus patients treated at MTD in Phase I).
- To assess the safety and tolerability of this regimen in these patients.
- To assess the incidence of cardiotoxicity in these patients treated with this regimen.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland
- Bon Secours Hospital
-
Cork, Ireland
- Cork University Hospital
-
Dublin, Ireland
- Beaumont Hospital
-
Dublin, Ireland
- St James's Hospital
-
Dublin, Ireland
- St. Vincent's University Hospital
-
Dublin, Ireland
- Mater Private Hospital
-
Dublin, Ireland
- Mater Misercordiae University Hospital
-
Galway, Ireland
- University Hospital Galway
-
Limerick, Ireland
- University Hospital Limerick
-
Waterford, Ireland
- Waterford Regional Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained prior to any study-related procedures.
- Female patients, age ≥ 18 years, who are either post menopausal (post-menopausal status will be defined as patients who are amenorrheic for > 1 year or for a shorter duration if FSH, LH and/or oestradiol levels are within the post-menopausal range), surgically sterile or practicing an effective method of birth control agreed with the patients study physician. Women of childbearing potential should use an effective contraceptive ( such as non hormonal intra uterine device (IUD), condoms, sexual abstinence or vasectomised partner).during treatment and up to 6 months following discontinuation of therapy.
- Histologically confirmed metastatic breast cancer
- Documented HER2 overexpression (IHC 3+ or FISH or CISH positive)
- At least one measurable lesion according to RECIST criteria. Patients with bone only disease are not eligible.
- Patients with controlled brain metastasis are eligible.
- Documented disease progression. Progression for entry is defined as appearance of any new lesion not previously identified or increase of 25% or more in existent lesion from previous CT scan and must be documented
- Prior treatment must have contained trastuzumab and taxane. Patients may have been treated with Lapatinib previously.
- Life expectancy of at least 12 weeks
- ECOG Performance Status of ≤ 2
- Left ventricular ejection fraction (LVEF) ≥ 55%, as measured by Echocardiogram or MUGA Scan (within 14 days prior to first infusion), and no documented history of uncontrolled or symptomatic angina, arrhythmias or congestive heart failure within the previous 6 months
Adequate bone marrow, haematological, hepatic and renal function defined as:
- Absolute Neutrophils Count ≥ 1.5 x 109/L
- Platelet Count ≥ 100 x 109/L
- Haemoglobin ≥ 9.0 g/dL
- Calculated creatinine clearance ≥ 40 mL/min
- Total bilirubin ≤ ULN. Patients with Gilbert's syndrome prior to study entry must have total bilirubin < 3 x ULN.
- Alkaline Phosphatase and AST or ALT within the parameters specified in protocol
- Patients must have recovered from clinically significant side effects associated with prior radiotherapy and chemotherapy
- Able to swallow and retain oral medication.
- Formalin-fixed paraffin-embedded tissue from archived tumour tissue samples available (from the primary or metastatic tissue.
Patients meeting any of the following exclusion criteria are not eligible for enrolment into this study:
Exclusion Criteria:
- Pregnant or lactating women
- Prior anthracycline chemotherapy with a lifetime dose exceeding 360 mg/m2 doxorubicin or 550 mg/m2 epirubicin
- Documented history of poorly controlled hypertension), arrhythmia, clinically significant valvular disease, angina requiring treatment, transmural infarction, myocardial infarction within the previous 6 months
- Concurrent disease that would make the patient inappropriate for study participation, or any other serious medical disorder that would interfere with the patient's safety
- Dementia, altered mental status, or any other psychiatric condition that would interfere with the patient's safety or informed consent
- Active or uncontrolled bacterial, viral or fungal infection.
- History of other malignancy. However patients who have been disease free for 5 years, or patients with a history of resected non-melanoma skin cancer or successfully treated in situ cancer are eligible
- Concurrent cancer therapy (chemotherapy, immunotherapy, biologic therapy, hormonal therapy, or within 4 weeks preceding the first dose of investigational product)
- Unresolved or unstable, serious toxicity from prior administration of another investigational product
- Concurrent treatment with an investigational drug within 4 weeks preceding the first dose of investigational product
- Known hypersensitivity to lapatinib and Myocet™ or their excipients
- Any other contraindications for lapatinib and Myocet™
- Receive concurrent treatment with prohibited medications. Zometa for patients with bone metastasis is allowed. If the patient is on Zometa at start of the study, it should be continued throughout the duration of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lapatinib (Tyverb™) and (Myocet™)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal dose for lapatinib plus myocet
Time Frame: 6 months
|
Determination of the optimal dose for lapatinib plus Myocet™, in combination, in patients with HER2-positive metastatic breast cancer following disease progression during, or after, treatment with trastuzumab and taxanes as measured by MTD (Phase I)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From registration to death
|
overall survival time (OS - time from registration to death from any cause) as assessed by standard RECIST criteria
|
From registration to death
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICORG 10-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Her2 Positive Metastatic Breast Cancer
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
Pravin T.P KaumayaNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoma | EGFR OverexpressionUnited States
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
Clinical Trials on non-pegylated liposomal doxorubicon (Myocet™)
-
Borstkanker Onderzoek GroepRoche Pharma AG; Teva PharmaCompletedMetastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of BreastNetherlands
-
Catharina Ziekenhuis EindhovenSanofi; CephalonCompletedBreast Cancer | Neoplasm MetastasisNetherlands
-
Laurence J.C. van WarmerdamSanofi; CephalonTerminatedBreast Cancer | Neoplasm MetastasisNetherlands
-
Prof Dirk EllingCompletedBreast CancerGermany
-
MedSIRRoche Pharma AG; ExperiorCompleted
-
Merck Sharp & Dohme LLCCompletedPneumococcal InfectionsUnited States, Korea, Republic of, Spain, Taiwan
-
German Breast GroupRoche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor PharmaCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
Mural Oncology, IncMerck Sharp & Dohme LLCActive, not recruitingFallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal CancerCanada, United States, France, Spain, Korea, Republic of, Austria, United Kingdom, Taiwan, Germany, Belgium, Czechia, Australia, Singapore, Italy
-
Yonsei UniversityRecruitingUterine Cervical Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Vulvar Cancer | Clear Cell Carcinoma | Vagina NeoplasmKorea, Republic of
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingFallopian Tube Cancer | Solid Tumor | Epithelial Ovarian Cancer | Peritoneal CancerUnited States, Australia, Bulgaria, Bosnia and Herzegovina, Georgia, Korea, Republic of, Serbia